The strong durability and immunogenicity data support EVX-01's clinical promise; traders should position ahead of the H2 2026 three-year data readout, which could serve as a major value driver. Watch for potential partnership or licensing interest ahead of data disclosure.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 7 $3.80entry
- T+1 · 7mo ago +6.84%α +4.30% · $4.06
- T+5 · 7mo ago +8.95%α +3.62% · $4.14
- T+20 · 7mo ago +20.26%α +10.48% · $4.57
- T+60 · 5mo ago −10.26%α −23.53% · $3.41
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion announced the successful completion of the one-year extension of its phase 2 trial for its personalized cancer vaccine EVX-01, with three-year clinical efficacy data expected in the second half of 2026. The trial has already shown a 75% Objective Response Rate and high durability, with 92% of patients still responding at two years and no relapses observed.
Key Facts
- Phase 2 trial extension completed; final three-year data expected in H2 2026
- Objective Response Rate of 75% (12 of 16 patients) with 4 complete responses
- 92% of patients maintained response at two-year follow-up; no relapses observed
- EVX-01 induced immune response in 100% of patients; 81% of targeted neoantigens generated potent T-cell responses
- Vaccine evaluated in advanced melanoma, combining EVX-01 with Keytruda® followed by monotherapy in year three
Financial Impact
Potential catalyst for value inflection pending 2026 data readout; current market cap of $31M reflects high risk/reward profile
Risk Factors
- Clinical trial results remain early-stage with small sample size (n=16)
- Future data may not maintain current efficacy or durability trends
- High market expectations could lead to sell-off if 2026 data is merely incremental
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3269035 |
Track record
50 reports on EVAX
6 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers